With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers

Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.